Research across Dementia
Related studies from across the Dementia family.
11 trials tracked for Frontotemporal dementia: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 71 citations.
Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
In a large Phase 3 trial (N=421), an attention-control condition was evaluated for frontotemporal dementia, but no specific outcome results were reported 1.
A Phase 2 trial (N=33) found that AL001 increased CSF progranulin (PGRN) levels by 59.73% to 198.16% and plasma PGRN by 151.32% to 188.12% over time 2.
The Building Better Caregivers Workshop (N=418) showed mixed results: depression scores (PHQ-8) were 5.7 vs 7.1, stress scores 6.0 vs 5.9, and caregiver self-efficacy 5.4 vs 5.1, with no p-values reported 6.
AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
Related studies from across the Dementia family.